Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib vs gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).

Authors

C. Zhou

Shanghai Pulmonary Hospital, Tongji University, Shanghai, China

C. Zhou , Y. L. Wu , G. Chen , J. F. Feng , X. Liu , C. Wang , S. Zhang , J. Wang , S. Zhou , S. Ren , S. Lu , L. Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.

First Author: Helena Alexandra Yu

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

First Author: Caicun Zhou

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s).

First Author: Tony Mok

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.

First Author: Yi Long Wu